Core Viewpoint - Chuang'er Bio has officially terminated its IPO preparation for the Beijing Stock Exchange after three years of efforts, marking a significant setback in its capital market ambitions [1]. Company Overview - Chuang'er Bio specializes in medical devices and bio-skincare products, having developed large-scale sterile extraction technology for bio-medical grade active collagen. The company holds two Class III and two Class II medical device registration certificates [2]. - The market share of Chuang'er Bio's collagen products in China's pharmaceutical-grade collagen market was 3.04% in 2017, 3.40% in 2018, and 5.23% in 2019 [2]. IPO Journey - The company's IPO journey has faced challenges, including an attempt to list on the Sci-Tech Innovation Board in 2020, which was followed by a withdrawal of the application in 2021 and a subsequent shift to the Beijing Stock Exchange [2]. - In July 2023, Chuang'er Bio signed a listing advisory agreement with Guotou Securities and submitted the listing advisory filing materials to the Guangdong Securities Regulatory Bureau. However, due to unresolved shareholder equity freeze issues, the advisory agreement was terminated on December 25, 2025 [2][3]. Shareholder Issues - The company did not disclose details about the shareholder equity freeze in its announcement, but it is directly related to its second-largest shareholder, Ding Yumei, who holds 365,360 shares, accounting for 4.30% of the company. This portion of shares is entirely frozen and not tradable [3]. - Ding Yumei is also known as the ex-wife of Xu Jiayin, the former chairman of the now-defunct China Evergrande Group. Chuang'er Bio previously collaborated with Ding Yumei's company on a skincare product project, which was ultimately terminated, leading to the recovery of a prepayment of 5 million yuan [5][6]. Legal and Financial Context - Ding Yumei's equity freeze is linked to the debt liquidation issues surrounding Evergrande. In 2022, she was reported to have reached a "technical divorce" with Xu Jiayin, interpreted as a financial separation to avoid debt liabilities [7]. - In March 2024, a lawsuit was initiated by the liquidators of China Evergrande to recover approximately $6 billion in dividends and compensation from Xu Jiayin, Ding Yumei, and several former executives. This legal action has resulted in global asset freezing orders against Ding Yumei [7].

Core Insights - The "Qihang·2025 Financial Summit" was successfully held in Beijing, focusing on "New Starting Point, New Momentum, New Journey," gathering hundreds of leaders and guests from regulatory bodies, industry associations, financial institutions, listed companies, and media [1] - The "Jizhi Award" was announced, with Juzhi Biotechnology winning the "Outstanding Growth Enterprise" award, aimed at setting high-quality development benchmarks and guiding listed companies to focus on their main business and continuous innovation [2][3] Company Performance - Juzhi Biotechnology demonstrated strong growth resilience in a sluggish market, achieving a revenue of 3.113 billion yuan in the first half of 2025, a year-on-year increase of 22.52%, and a net profit of 1.182 billion yuan, up 20.23% [4] - The company's main business focuses on professional skincare products and health foods, with professional skincare products accounting for over 99% of its core revenue [4] Brand Performance - The flagship brand, Kefu Mei, generated 2.54 billion yuan in revenue in the first half of 2025, a 22.7% increase, representing 81.7% of total revenue, with key products performing well in major sales events [5] - The Keli Jin brand also showed strong performance with a revenue of 503 million yuan, up 26.9%, and its star product ranked in the top 4 of the Tmall sales list for facial masks [5] Future Outlook - Juzhi Biotechnology plans to continue focusing on its main business, enhancing innovation, strengthening its omnichannel layout, and expanding into medical aesthetics and overseas markets to contribute to the high-quality development of the biological skincare industry [5]

Core Insights - Shenzhou Holdings' subsidiary, KJ, signed strategic cooperation agreements with four industry leaders in various sectors, indicating a strong commitment to enhancing smart supply chain solutions [1] Group 1: Strategic Partnerships - KJ has partnered with Lenovo Zhixiang, Jianmin Pharmaceutical, Zhenyan Biotechnology, and Heidi Garden, representing sectors such as office printing, healthcare, skincare, and horticulture [1] - The collaboration aims to provide customized smart supply chain solutions tailored to the specific needs and characteristics of each industry [1] Group 2: Company Expertise - Shenzhou Holdings emphasized that KJ's extensive industry experience and deep technological foundation are key factors that ensure the reliability of these partnerships [1]